GURUFOCUS.COM » STOCK LIST » USA » NAS » VectivBio Holding AG (NAS:VECT) » Definitions » Cash Receipts from Loans
Switch to:

VectivBio Holding AG (NAS:VECT) Cash Receipts from Loans

View and export this data going back to 2021. Start your Free Trial

Cash Receipts from Loans only applicable to companies reporting Cash Flow from Operations in direct method.

VectivBio Holding AG (NAS:VECT) Business Description

VectivBio Holding AG logo
Traded in Other Exchanges
Aeschenvorstadt 36, Basel, CHE, 4051
VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. The product candidate is apraglutide, which is a next generation, long-acting synthetic peptide analog of glucagon-like peptide-2, or GLP-2, which is developed as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome.